Liquid Biopsy: It's the Bloody Truth!

Clin Cancer Res. 2021 Apr 1:clincanres.0531.2021. doi: 10.1158/1078-0432.CCR-21-0531. Online ahead of print.ABSTRACTLiquid biopsy is a promising clinical tool that can provide critical information for prognostication and which may inform treatment decisions in men with metastatic castration resistant prostate cancer (mCRPC). Here we discuss the Foundation Medicine plasma cell free tumor DNA (ctDNA) assay, its pros and cons, and potential clinical utility.PMID:33795259 | DOI:10.1158/1078-0432.CCR-21-0531
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Source Type: research